Pharmacology
Conditions
Keywords
Pharmacology, Pharmacokinetics, Pharmacodynamics, Abiraterone acetate, Food intake, Caucasion, Japanese, Healthy
Brief summary
The purpose of this study is to evaluate the effect of timing of food intake on systemic abiraterone exposure observed in healthy adult Japanese and Caucasian men.
Detailed description
This is a randomized (individuals will be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), single dose, 4-way crossover study of abiraterone acetate in approximately 48 healthy adult Japanese and Caucasian men. For the crossover design, the treatment sequences are defined as follows: 1 - ADBC, 2 - BACD, 3 - CBDA, and 4 - DCAB; where Treatment A = abiraterone acetate administered in the fasted state, Treatment B = standardized meal administered 1 hour after abiraterone acetate dose, Treatment C = standardized meal administered 2 hours after abiraterone acetate dose, and Treatment D = standardized meal administered 2 hours before and 2 hours after abiraterone acetate dose. This study will consist of a screening period followed by four open-label treatment periods separated by a washout period of at least 14 days between dosing. Eligible participants will be randomly assigned on Day 1 to 1 of 4 treatment sequences that differ with regard to timing of food intake before and/or after dosing with a single dose of 1000 mg of abiraterone acetate. Serial pharmacokinetic (study of what the body does to a drug) samples will be collected during the open-label treatment phase as detailed in the protocol. Safety will be monitored throughout the study. End-of-study assessments will be performed on Day 4 of Period 4 or upon early withdrawal.
Interventions
DRUGAbiraterone: Treatment A
1000 mg abiraterone acetate administered in the fasting state
DRUGAbiraterone: Treatment B
Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
DRUGAbiraterone: Treatment C
Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
DRUGAbiraterone: Treatment D
Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
25 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy Caucasian and Japanese male individuals. * Body mass index between 18 and 30 kg/m2. * Body weight \>=50 kg. * A normal 12-lead electrocardiogram.
Exclusion criteria
* History of or current clinically significant medical illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results. * Presence of sexual dysfunction (abnormal libido, erectile dysfunction, etc.) or any medical condition that would affect sexual function. * History of alcohol consumption of more than 4 drinks daily within 1 year prior to screening and unwillingness to abstain from alcohol-containing food or beverages from within 24 hours before Day-1 through study completion. * History of, or a reason to believe a participant has a history of drug or alcohol abuse within the past 5 years. * Positive test for human immunodeficiency virus 1 and 2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies. * History of smoking or use of nicotine-containing substances within the previous 2 months, as determined by medical history or participant's verbal report.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in mean plasma concentrations of abiraterone | Up to Day 4, treatment period 4 |
Secondary
| Measure | Time frame |
|---|---|
| Mean plasma concentrations of abiraterone | Up to Day 4, treatment period 4 |
| Maximum plasma concentration of abiraterone | Up to Day 4, treatment period 4 |
| Time to reach the maximum plasma concentration of abiraterone | Up to Day 4, treatment period 4 |
| Area under the plasma concentration-time curve from time 0 to time the last quantifiable concentration of abiraterone | Up to Day 4, treatment period 4 |
| Time to last quantifiable plasma concentration of abiraterone | Up to Day 4, treatment period 4 |
| Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of abiraterone | Up to Day 4, treatment period 4 |
| First-order rate constant associated with the terminal portion of the curve of abiraterone | Up to Day 4, treatment period 4 |
| Percentage of area under the plasma concentration-time curve from time 0 to infinite time obtained by extrapolation of abiraterone | Up to Day 4, treatment period 4 |
| The number of participants affected by an adverse event | Up to the end of the study (4 days after final dose of study drug) or early withdrawal |
| Area under the plasma concentration-time curve from time 0 to infinite time of abiraterone | Up to Day 4, treatment period 4 |
Countries
United States
Outcome results
None listed